Teva to present Pivot to Growth strategy at J.P. Morgan Healthcare Conference

Teva will present its Pivot to Growth transformation and 2025 financial outlook at the 44th J.P. Morgan Healthcare Conference, with CEO Richard Francis scheduled to speak. The company disclosed 2025 guidance ranges including revenues of $16.8–$17.0 billion and other non-GAAP metrics.

Teva will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference, with President and CEO Richard Francis scheduled to meet with investors and outline milestones from 2025 and the outlook for 2026 and beyond. The company described a “Pivot to Growth” strategy that emphasizes building a late-stage innovative pipeline while maintaining its generics business. The announcement lists key innovative brands and clinical assets the company says will support longer-term growth. A live webcast of the presentation will be available on Teva’s investor relations website, and an archived version will be posted within 24 hours and accessible for up to 30 days. Key details: - The article mentions Teva is accelerating its Pivot to Growth strategy and highlights brands AUSTEDO, AJOVY and UZEDY and clinical assets such as olanzapine LAI, DARI, duvakitug, emrusolmin, and anti-IL-15. - Expected 2025 guidance ranges include revenues of $16.8–$17.0 billion (GAAP), operating margin ~26.2%–27.1%, adjusted EBITDA $4.8–$5.0 billion, diluted EPS $2.55–$2.65, tax rate 15%–18%, free cash flow $1.6–$1.9 billion, and net leverage ~2.5x–2.9x. The article notes some additional contributions tied to duvakitug milestones. - Teva presented a multi-year path to targets through 2027 and 2030: revenues flat to slightly down in 2026 versus 2025, low-single digit growth in 2027, and a mid-single digit CAGR to 2030; operating profit rising to about 30% by 2027 and above 30% by 2030; free cash flow rising to >$2.7 billion by 2027 and >$3.5 billion by 2030; and net leverage moving toward ~2.0–2.2x in 2026 and below 2x thereafter. - The announcement clarifies that revenues are presented on a GAAP basis while other metrics are non-GAAP, and it includes a cautionary note that forward-looking statements are subject to risks and uncertainties. - The article identifies planned transformation program savings and timelines, citing cumulative savings of roughly $450–$500 million by 2026 and about $700 million by 2027. Summary: Teva presented its strategic shift toward more innovative medicines while retaining a generics foundation and provided detailed 2025 guidance ranges and multi-year targets through 2030. The company signaled continuing focus on disciplined capital allocation and on improving leverage and cash generation; a live webcast of the presentation is available and an archived recording will follow. Undetermined at this time